Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...
Biocon Biologics has expanded its footprint in Malaysia, delivering 100 million insulin cartridges to the country’s Ministry of Health since entering the market in 2016. The company’s integrated ...
On August 31, 2022, Biocon Biologics released a statement regarding three recent on-site FDA inspections of seven manufacturing facilities spanning two sites in Bengaluru, India and one site in Johor, ...
Shares of Biocon Ltd surged as much as 5 per cent during the trading session on Monday after the United States Food and Drug Administration (USFDA) cleared the Malaysia unit, ending regulatory hurdles ...
Biocon Biologics announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the milestone of supplying 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s ...
Biocon Limited announced that its subsidiary Biocon Biologics has received a six-months extension from the Malaysia government towards its insulin supply contract. With this extension, the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results